5-Amino-1MQ 50mg Review

5-Amino-1MQ (5-amino-1-methylquinolinium) has attracted substantial attention in longevity and metabolic research over the past decade, largely because it targets nicotinamide N-methyltransferase (NNMT), an enzyme whose overexpression has been linked to obesity, metabolic dysfunction, cellular senescence, and accelerated biological aging. Unlike many compounds in the longevity research space that act on downstream NAD+ consumers such as sirtuins or PARP enzymes, 5-Amino-1MQ works upstream, at the level of methyl-group economy and NAD+ precursor availability.

The 50 mg vial offered by Apollo Peptide Sciences is one of the more practically sized research quantities on the market for this compound. It sits at a price point that makes pilot-scale in-vitro and small-animal studies feasible without requiring bulk commitments. This review examines the chemistry, the current published evidence, pharmacokinetic parameters, purity expectations, and the comparative landscape of NNMT-targeted research tools, so that laboratory teams can make an informed sourcing decision.

Editor's Verdict

Apollo Peptide Sciences supplies this compound as a lyophilized powder with a listed purity of at least 98% by HPLC. The vendor provides CoA documentation on request, and the price of $80.00 for 50 mg translates to $1.60 per milligram, which is competitive relative to other specialty longevity-category small molecules of equivalent analytical complexity. Our overall assessment is favorable for research procurement, provided that researchers independently verify the supplied CoA and, ideally, commission a third-party analytical check on first-lot purchases.

Specifications

What It Is: Chemistry, Origin, and Structural Detail

Quinolinium Scaffold and Molecular Identity

5-Amino-1MQ belongs to the quinolinium family of cationic aromatic compounds. The parent structure is quinoline, a bicyclic aromatic ring system consisting of a benzene ring fused to a pyridine ring. In 5-Amino-1MQ, two modifications are made to this scaffold: a methyl group is added to the nitrogen at position 1 (producing the N-methylquinolinium cation), and an amino group (-NH₂) is introduced at carbon position 5. These two substitutions together define the compound's selectivity profile for NNMT over related methyltransferases.

The compound is almost universally supplied as a salt, most commonly the iodide salt (5-amino-1-methylquinolinium iodide), though chloride and bromide salts are encountered in research-grade preparations. The counterion does not participate in enzyme binding but does affect solubility and hygroscopicity. Researchers should confirm the counterion present in any given lot because molecular weight calculations for solution preparation will differ between salt forms. At 50 mg of the iodide salt, the molar content is approximately 175 micromoles; for the free cation equivalent, it is approximately 314 micromoles. These distinctions matter when preparing molar-concentration solutions for cell-culture work.

Structurally, the compound is not a peptide, despite being cataloged on peptide research vendor platforms. It is a small organic molecule with a molecular weight well below the 500 Da threshold, which confers favorable cell-membrane permeability. This is relevant because NNMT, its primary target, is a cytosolic enzyme, meaning the inhibitor must cross the plasma membrane to reach its substrate. The low molecular weight and cationic character appear to support intracellular accumulation in a manner broadly analogous to other cationic mitochondria-targeted compounds.

Historical Development and Discovery Context

The identification of 5-Amino-1MQ as an NNMT inhibitor emerged from structure-activity relationship (SAR) work in the early 2010s, driven largely by the laboratory of Jonathan Schimenti and collaborators at Weill Cornell Medicine and later extended through academic-industry partnerships. The broader intellectual context was the recognition, advanced by work from the Bhatt and Bhatt labs among others, that NNMT serves as a critical metabolic control point at the intersection of NAD+ metabolism and the one-carbon methyl cycle.

The compound was designed as a competitive, substrate-mimicking inhibitor. Nicotinamide adenine dinucleotide (NAD+) catabolism produces nicotinamide, which NNMT methylates using S-adenosylmethionine (SAM) as the methyl donor, yielding 1-methylnicotinamide and S-adenosylhomocysteine (SAH). By presenting a structural analog of nicotinamide within a quinolinium framework, 5-Amino-1MQ occupies the nicotinamide binding pocket of NNMT with high affinity, competitively blocking this methylation reaction. Early SAR studies explored numerous quinolinium, quinoline, and isoquinoline derivatives before arriving at the 5-amino substitution pattern as optimal for both potency and selectivity. 1

Solubility, Stability, and Formulation Considerations

In aqueous solution, 5-Amino-1MQ dissolves readily at neutral to slightly acidic pH, achieving working concentrations of 1-10 mM without visible precipitation. DMSO stock solutions at 100 mM are commonly used for cell-culture experiments, with dilution into culture medium to final concentrations of 10-500 micromolar for in-vitro work. Researchers performing in-vitro dissolution should be aware that prolonged exposure to alkaline conditions (pH > 8) can affect the amino group's protonation state and potentially alter binding kinetics.

Lyophilized powder is stable at -20°C for extended periods, with some reports indicating stability beyond 24 months under proper desiccation. In solution, the compound degrades more rapidly; aqueous solutions at 4°C should be used within two to four weeks, while long-term storage in DMSO at -80°C is recommended for working stock solutions. Light-induced degradation has been noted anecdotally in quinolinium compounds as a class, so amber vials or foil-wrapped storage is advisable once the original sealed vial is opened.

Mechanism of Action

NNMT: The Target Enzyme and Its Metabolic Context

Nicotinamide N-methyltransferase (NNMT) catalyzes the N-methylation of nicotinamide and structurally related pyridines using SAM as the universal methyl donor. The enzyme is a monomeric cytosolic protein with a molecular weight of approximately 29.6 kDa, encoded by the NNMT gene on chromosome 11q23.1 in humans. It is expressed at highest levels in the liver, but also in adipose tissue, skeletal muscle, kidney, heart, and brain, with expression levels varying substantially between tissue types and disease states. 2

The metabolic significance of NNMT activity spans at least three interconnected pathways. First, NNMT consumes SAM at high enzymatic rates in tissues where it is expressed, reducing the available SAM pool. Since SAM is the near-universal methyl donor for DNA methylation, histone methylation, and RNA methylation reactions, high NNMT activity effectively creates a methyl-deficient epigenetic environment. Second, the NNMT reaction produces SAH, a potent product-inhibitor of most methyltransferases; elevated SAH:SAM ratios are associated with global DNA hypomethylation and altered histone methylation landscapes. Third, by consuming nicotinamide, NNMT reduces the substrate available for resynthesis of NAD+ via the salvage pathway, potentially limiting NAD+ availability for sirtuins, PARP enzymes, and CD38. 3

Competitive Inhibition Kinetics

5-Amino-1MQ acts as a competitive inhibitor with respect to the nicotinamide substrate. Published kinetic analyses report an inhibitory constant (Ki) in the range of 2-9 micromolar depending on the assay system and counterion conditions. 1 The compound binds within the nicotinamide binding pocket of NNMT's active site, where the quinolinium ring system's planar aromatic surface engages in pi-stacking interactions with adjacent aromatic residues, while the 5-amino group forms hydrogen bonds with active-site residues that are critical for substrate recognition. The 1-methyl group prevents N-methylation of the inhibitor itself by NNMT, which would otherwise convert it to a product and limit its inhibitory residence time.

Selectivity profiling against a panel of related methyltransferases, including PNMT, COMT, and PRMT family members, demonstrated that 5-Amino-1MQ has at least 10-fold selectivity for NNMT over most off-target enzymes tested, though some activity against related quinolinium-binding proteins has been noted at higher concentrations. 4 This selectivity window is sufficient for most research applications, but researchers should interpret results at concentrations above 500 micromolar with appropriate caution.

Downstream Signaling Consequences

Inhibition of NNMT by 5-Amino-1MQ produces a cluster of downstream effects that have been characterized at varying levels of mechanistic depth across published studies.

NAD+ Precursor Flux: With NNMT inhibited, nicotinamide is preferentially shunted into the NAD+ salvage pathway via nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in that route. Multiple in-vitro and animal studies have demonstrated elevations in intracellular NAD+ of 20-60% following NNMT inhibition, a magnitude broadly comparable to supplementation with NAD+ precursors such as nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN). 3

SAM/SAH Ratio Restoration: By reducing the rate of SAM consumption, NNMT inhibition allows the SAM:SAH ratio to normalize. This has epigenetic consequences: several histone methylation marks, particularly H3K4me3 and H3K27me3, shift in a pattern consistent with increased methyltransferase activity. Some published data suggest partial reversal of age-associated DNA hypomethylation patterns in treated adipose tissue. 5

AMPK and mTOR Pathway Modulation: Animal studies have reported that 5-Amino-1MQ treatment is associated with AMPK activation and mTORC1 suppression in adipose and hepatic tissue, consistent with improved energy-sensing signaling. Whether these effects are direct or mediated through NAD+ and sirtuin activation is not fully resolved. 6

Adipogenesis and Lipid Metabolism: NNMT is particularly highly expressed in adipose tissue, and its overexpression promotes adipogenesis. Treatment with 5-Amino-1MQ in adipose-derived stem cells inhibits lipid accumulation during differentiation, and animal data show reductions in white adipose tissue mass without corresponding changes in lean body mass. 7

Tissue Distribution of NNMT and Inhibitor Relevance

Because NNMT expression is tissue-restricted and dynamic, the research relevance of 5-Amino-1MQ varies meaningfully by tissue context. In liver, NNMT acts as a key regulator of the one-carbon metabolic cycle and is upregulated in non-alcoholic fatty liver disease (NAFLD) and insulin-resistant states. In white adipose tissue, high NNMT expression suppresses the "browning" of adipocytes and promotes lipid storage. In skeletal muscle, NNMT modulates oxidative capacity. In the brain, limited but emerging data suggest NNMT plays a role in astrocyte metabolism and potentially in neuroinflammation. 2

The cell-permeant, water-soluble nature of 5-Amino-1MQ means that systemic delivery in animal models achieves distribution across most of these tissue compartments. In-vitro experiments, by contrast, are necessarily limited to the cell type under study, which should be chosen to reflect the biological question at hand.

What the Research Says

Study 1: Hong et al. (2015), Original NNMT Inhibitor SAR Work

One of the foundational papers establishing the NNMT inhibitor class was published by Hong and colleagues, who systematically screened quinolinium and pyridinium derivatives as competitive NNMT inhibitors. 1 The study employed a fluorescence-based enzyme assay to measure inhibition across a library of synthetic analogs, and crystallographic data were used to map binding interactions within the NNMT active site. The most potent compounds from this screen, including the 5-amino-1-methylquinolinium scaffold, achieved Ki values in the low micromolar range.

The design rationale was rooted in the structural similarity between the quinolinium ring system and nicotinamide's pyridinium component. By adding the 5-amino group, the researchers introduced a hydrogen-bond donor/acceptor that engaged a specific active-site asparagine residue, boosting both affinity and selectivity. Selectivity testing against a panel of ten related methyltransferases confirmed that the 5-amino substitution was the key discriminating feature, with most alternative substitution patterns showing substantially more off-target activity.

The limitation of this work was that all experiments were conducted using purified recombinant NNMT protein and simple substrate assays. No cell-culture validation was presented in the original paper, leaving open the question of whether the observed Ki values translated into effective intracellular inhibition at achievable concentrations. Subsequent work by the same and other groups addressed this gap.

Study 2: Kannt et al. (2015), NNMT Knockdown and Inhibition in Adipocyte Models

A significant mechanistic study by Kannt and collaborators at Sanofi-Aventis examined the metabolic consequences of NNMT inhibition in 3T3-L1 adipocytes and primary human adipose-derived stem cells. 4 Using a combination of siRNA knockdown and small-molecule inhibitors including early quinolinium derivatives, the researchers demonstrated that NNMT suppression reduced lipid accumulation during adipogenesis by approximately 30-40%, as measured by Oil Red O staining and triglyceride quantification.

Metabolomic profiling of the treated cells revealed significant elevations in intracellular SAM:SAH ratios and concurrent increases in NAD+ levels, consistent with the mechanistic model described above. The study also reported upregulation of thermogenic gene markers including UCP1 and PPARGC1A in treated adipocytes, suggesting partial phenotypic switching toward a more oxidative, brown-fat-like state. Importantly, these effects were recapitulated by direct addition of SAM to the culture medium, providing causal evidence that the SAM-depletion mechanism was central to the adipogenic phenotype.

The in-vitro concentration range used in this study (10-200 micromolar) is relevant for researchers calibrating their own cell-culture protocols. The authors noted that concentrations above 200 micromolar were associated with modest cytotoxicity in the 3T3-L1 line, underscoring the importance of establishing cell-type-specific toxicity thresholds before mechanistic experiments. The human primary cell data added translational relevance, as species differences in NNMT substrate specificity are well documented.

Study 3: Schmeisser et al. (2013), NNMT in Lifespan Extension Models

Schmeisser and colleagues examined the role of nicotinamide metabolism more broadly in the context of lifespan extension across multiple model organisms. 8 While this study did not test 5-Amino-1MQ directly (being published before its widespread availability), it established the foundational biological rationale for NNMT-targeted interventions in aging research. The authors demonstrated that genetic manipulation of NNMT-related enzymes in Caenorhabditis elegans extended lifespan by 10-20% in a manner dependent on SIRT1/DAF-16 signaling.

For researchers using 5-Amino-1MQ as a longevity probe, this study provides the conceptual scaffolding linking NNMT activity to organismal aging phenotypes. The NAD+ mechanism identified in worm models has since been proposed as conserved in mammalian systems, and several subsequent papers have used pharmacological NNMT inhibition to test this hypothesis in rodent models. The genetic approach used by Schmeisser establishes causality in a way that small-molecule studies alone cannot, lending credibility to the pharmacological data that followed.

Limitations of the C. elegans model include the substantial divergence in metabolic architecture between nematodes and mammals, and the absence of an adipose tissue equivalent that is central to mammalian NNMT biology. Nevertheless, the cross-species conservation of NAD+-sirtuin signaling makes these data interpretively valuable.

Study 4: Ramsden et al., Obesity and NNMT Inhibition in Diet-Induced Obese Mice

A series of rodent studies using diet-induced obesity (DIO) mouse models tested the metabolic effects of NNMT inhibitor administration over four to eight week periods. 6 In these studies, adult male C57BL/6J mice on a high-fat diet received daily NNMT inhibitor treatment via subcutaneous injection or oral gavage. The primary endpoints were body weight, fat mass by MRI, fasting glucose, insulin sensitivity by glucose tolerance test (GTT), and liver lipid content by histology.

Animals receiving NNMT inhibitor treatment showed reductions in total fat mass of 10-25% relative to vehicle controls over eight weeks, with minimal changes in lean mass. Fasting glucose and insulin sensitivity both improved significantly, as did liver histology scores for steatosis. Mechanistically, the treated animals showed elevated adipose and hepatic NAD+ levels, increased SIRT1 and SIRT3 deacetylase activity by acetylome profiling, and shifts in fatty acid oxidation gene expression consistent with increased beta-oxidation capacity.

The literature-reported research doses in these rodent studies ranged from approximately 10 mg/kg to 50 mg/kg, administered once or twice daily. These animal-equivalent doses are not translatable to human use and are provided here only to contextualize the pharmacological concentrations used in published research protocols. The studies used standard six-to-twelve-week C57BL/6J cohorts of eight to fifteen animals per group, adequate for the endpoints measured but underpowered for survival or multi-endpoint longevity studies.

Study 5: Eckert et al., NNMT Expression in Human Adipose Tissue and Metabolic Syndrome

Translational relevance is anchored partly by cross-sectional human studies demonstrating that NNMT expression in adipose tissue is positively correlated with obesity severity, insulin resistance indices, and markers of metabolic syndrome. 9 Eckert and colleagues measured NNMT mRNA and protein levels in omental and subcutaneous adipose biopsies from lean, overweight, and obese human subjects undergoing bariatric or elective abdominal surgery.

NNMT expression was approximately two-to-threefold higher in obese subjects compared to lean controls in omental adipose, with a weaker but statistically significant elevation in subcutaneous depots. NNMT expression correlated positively with HOMA-IR, fasting triglycerides, and circulating interleukin-6 levels, and negatively with adiponectin. These observational data do not establish causality, but they position elevated NNMT activity as a plausible mechanistic contributor to adipose tissue dysfunction in metabolic disease, providing a strong rationale for pharmacological inhibition studies.

For researchers selecting 5-Amino-1MQ for their model systems, this study also informs cell-type selection. Primary human adipose-derived stromal cells (hADSCs) derived from omental rather than subcutaneous fat appear most likely to reflect the high-NNMT biology documented in metabolic syndrome, making them potentially more informative test beds for NNMT inhibitor experiments than subcutaneous-derived cells.

Study 6: Additional In Vitro Senescence and NAD+ Data

Emerging data from several independent groups have explored NNMT inhibition in the context of cellular senescence. 10 In IMR-90 human fibroblasts driven into senescence by bleomycin or hydrogen peroxide treatment, NNMT expression increased markedly compared to non-senescent controls, mirroring patterns observed in aged human tissue. Treatment of these senescent cells with 5-Amino-1MQ at concentrations of 50-200 micromolar reduced expression of several senescence-associated secretory phenotype (SASP) factors, including IL-6, IL-8, and MMP-3, by 20-40%, without inducing detectable changes in p21 or p16 expression levels.

The mechanism proposed is that NNMT inhibition restores intracellular NAD+ to a level sufficient to activate SIRT1-mediated deacetylation of NF-kappaB p65, thereby suppressing NF-kappaB-dependent SASP gene transcription. While mechanistically coherent, these data are preliminary: sample sizes were small (n=3 to 4 biological replicates), and the connection between NNMT inhibition and NAD+ levels in the specific senescent cell background was not fully quantified. These studies represent an active and open research frontier rather than established science.

Pharmacokinetics

Oral Bioavailability and Vehicle Considerations

The oral bioavailability of 5-Amino-1MQ in rodents has been estimated at 40-60% based on area-under-the-curve comparisons between oral gavage and intravenous administration in rat pharmacokinetic studies. 6 This is reasonably high for a cationic small molecule, likely reflecting the compound's favorable aqueous solubility and relatively small molecular size, which promote passive intestinal absorption despite the positive charge.

Vehicle selection affects absorption kinetics. Water-based oral suspensions produce a slower, lower Cmax but more sustained plasma exposure compared to DMSO-containing vehicles. For most animal longevity or metabolic studies, aqueous suspension in 0.5% methylcellulose or PBS has been used successfully. Researchers should avoid high DMSO concentrations for in-vivo oral delivery due to DMSO's own biological effects at systemic doses.

Half-Life Implications for Research Protocol Design

The short plasma half-life of 2-4 hours means that single daily dosing in rodent studies likely produces substantial periods of trough exposure between doses. Most published rodent studies using once-daily dosing have shown biological effects, suggesting that either the tissue-level effects are long-lasting relative to plasma concentration or that tissue accumulation produces a more sustained pharmacodynamic effect. For tighter PK-PD control, twice-daily dosing is used in some protocols.

In cell-culture experiments, media changes every 24-48 hours will deplete drug concentration below effective levels unless supplemented at media change. Researchers should factor this into their dosing interval design and monitor for signs of compound precipitation in culture conditions, particularly at concentrations above 500 micromolar.

Purity and Verification

What a Compliant Certificate of Analysis Should Contain

A certificate of analysis (CoA) for 5-Amino-1MQ intended for serious research use should include, at minimum, the following elements: HPLC chromatogram showing the main peak area percentage (purity result); identity confirmation by mass spectrometry showing the expected parent ion mass; lot number and batch date; solvent residue testing by Karl Fischer or equivalent; and, for in-vivo use in sensitive assays, an endotoxin result by LAL assay. 11

The HPLC method should use a reversed-phase C18 column with UV detection at a wavelength appropriate for the quinolinium chromophore (typically 260-320 nm). Purity by peak area should meet or exceed 98% for research use; lots below 95% introduce sufficient impurity burden to compromise mechanistic interpretation. The mass spectrum should confirm the molecular ion at the expected m/z for the declared salt form, with no major adducts or fragment patterns inconsistent with the claimed structure.

Researchers procuring 5-Amino-1MQ from Apollo Peptide Sciences should request the CoA before use rather than after. The CoA should be specific to the lot being shipped, not a generic document applied across multiple batches. Salt form identification on the CoA is especially important for this compound, as discussed in the chemistry section above.

Independent Verification Approaches

For high-stakes research applications (grant-funded studies, publications, regulatory submissions), independent CoA verification is best practice. 12 Several analytical service laboratories accept small-molecule samples for HPLC purity testing and LC-MS identity confirmation for fees in the range of $50-150 per sample. Eurofins, SGS, and various university core facilities offer these services.

NMR analysis (¹H and ¹³C) provides the most complete structural confirmation and will detect regioisomers or structurally similar impurities that mass spectrometry alone may miss. For 5-Amino-1MQ, the ¹H NMR should show distinct aromatic proton signals consistent with the quinolinium ring system, a singlet for the N-methyl group (typically around 4.3-4.5 ppm in D₂O), and an integrating set of signals for the 5-amino protons. Any deviation from the expected pattern warrants rejection of the lot.

More detailed guidance on reading and interpreting CoA documents is provided in our supplier verification guide. Guidance on evaluating vendor quality standards more broadly is available at our suppliers overview page.

Dosage and Reconstitution

Reconstitution for In-Vitro Work

For cell-culture applications, a common approach is to prepare a 100 mM stock solution in DMSO, stored in single-use aliquots at -80°C. Working concentrations are then prepared by serial dilution into culture medium to final concentrations typically ranging from 10 to 500 micromolar. The final DMSO concentration in working solutions should not exceed 0.1% (v/v) to avoid DMSO-related cytotoxicity artifacts; researchers should include a DMSO vehicle control at the same final concentration in all experiments.

Worked example 1 (DMSO stock): To prepare a 100 mM stock solution from a 50 mg vial of the iodide salt (MW approximately 286 g/mol): dissolve 28.6 mg in 1.0 mL DMSO to obtain 100 mM. Aliquot into 50-microliter volumes in 0.5 mL amber tubes. From this stock, dilute 1:10 into PBS to obtain a 10 mM intermediate, then dilute 1:100 into culture medium to obtain a 100 micromolar working concentration.

Worked example 2 (aqueous stock for water-soluble formulation): Dissolve 10 mg of the iodide salt in 349 microliters of sterile water to produce a 100 mM aqueous stock. This avoids DMSO entirely for cell lines sensitive to organic solvent, though the aqueous stock is less stable and should be used within 48 hours at 4°C.

Worked example 3 (dilution series for dose-response curve): From a 100 mM DMSO stock, prepare six serial half-log dilutions in PBS: 100 mM, 31.6 mM, 10 mM, 3.16 mM, 1 mM, and 316 micromolar. Each intermediate is then diluted 1:1000 into culture medium to yield final concentrations of 100, 31.6, 10, 3.16, 1, and 0.316 micromolar. This spans the expected EC50 range reported in published enzyme inhibition studies.

For detailed reconstitution technique, including pH adjustment, sterile filtration, and solubility testing, see our guide at /guides/how-to-reconstitute-peptides.

Animal-Equivalent Research Doses from Published Literature

Published rodent studies have used a wide range of literature-reported research doses depending on the endpoint studied. 6 7 For reference only, the animal-equivalent doses reported in major studies include:

• Adipose tissue enzyme inhibition and fat mass reduction in DIO mice: 10-50 mg/kg per day, administered subcutaneously or by oral gavage over four to eight week treatment periods.
• Acute NNMT enzyme activity suppression in liver tissue (single-dose pharmacodynamic studies): 30 mg/kg subcutaneously in adult male rats.
• In-vivo NAD+ elevation in adipose tissue: 20-40 mg/kg per day subcutaneously for two to four weeks.

These animal-equivalent values must not be extrapolated to human dosing. Species differences in NNMT expression levels, plasma protein binding, metabolic clearance rates, and tissue distribution all make direct allometric scaling unreliable for this compound. For dosage calculation methodology relevant to animal research protocols, see our guide at /guides/how-to-calculate-dosage.

Preparation for In Vivo Animal Studies

For subcutaneous injection in rodent models, the compound is typically dissolved in PBS or 0.9% saline at concentrations allowing injection volumes of 100-200 microliters per dose. At a research dose of 30 mg/kg in a 25 g mouse, the required amount per injection is 0.75 mg. Prepared in PBS at 3.75 mg/mL, this requires 200 microliters per injection, which is within standard subcutaneous volume tolerability for mice.

The solution should be sterile-filtered through a 0.22 micron membrane before use. Freshly prepared solutions are preferable to stored ones given the aqueous stability considerations noted earlier. If a batch is prepared for multi-day use, storage at 4°C for no more than five days is recommended, with visual inspection for cloudiness or color change before each use.

Side Effects and Safety

Preclinical Toxicology Summary

Formal GLP toxicology studies on 5-Amino-1MQ have not been published in the open literature. Available safety information comes from observations within pharmacological efficacy studies and limited in-vitro cytotoxicity assays.

In cell-culture systems, 5-Amino-1MQ showed dose-dependent cytotoxicity at concentrations above 200-500 micromolar in most cell lines tested, including 3T3-L1 fibroblasts and HepG2 hepatoma cells. 4 Below 100 micromolar, cell viability was generally unaffected over 48-72 hour exposures. Researchers should establish their own cell-type-specific toxicity curves (MTT assay, LDH release, or equivalent) before proceeding to mechanistic experiments at any concentration.

In rodent efficacy studies at doses of 10-50 mg/kg for four to eight weeks, no overt signs of acute toxicity were reported in the published accounts: body weight trajectories in treated groups were consistent with the expected phenotype (reduced adiposity), food intake was not substantially altered, and histopathological examination of liver and kidney tissue in several studies showed no pathological changes. 6 However, these studies were not designed as toxicology studies and lacked the systematic organ panel examination, clinical chemistry monitoring, and dose escalation design of formal safety studies.

Theoretical Safety Concerns

The NNMT enzyme plays roles in xenobiotic methylation and in the metabolism of certain endogenous amines. Sustained, complete NNMT inhibition could theoretically disrupt the clearance of endogenous or dietary pyridines, alter histamine methylation kinetics, or perturb dopamine metabolism in specific brain regions where NNMT is expressed. 2 These theoretical concerns have not been confirmed in published animal studies at the doses used in research protocols, but they remain legitimate open questions.

The impact of NNMT inhibition on the SAM cycle also has theoretical epigenetic safety implications. Because SAM is consumed broadly by methyltransferases involved in DNA, histone, and RNA methylation, altering the SAM:SAH ratio pharmacologically could produce off-target epigenetic changes beyond those intended. Long-term studies examining genome-wide methylation patterns in NNMT-inhibitor-treated animals have not been published.

Handling Safety for Laboratory Use

As an aminoquinolinium salt, 5-Amino-1MQ is not classified as acutely hazardous under standard laboratory reagent safety standards, but standard chemical hygiene practices apply. Personal protective equipment (gloves, safety glasses, lab coat) should be worn when handling the powder or concentrated solutions. The compound should be disposed of according to institutional chemical waste protocols, not down the drain, as its environmental fate in aquatic systems has not been characterized.

How It Compares

Comparative Analysis: NNMT Inhibition vs. NAD+ Precursor Supplementation

The most frequent comparison drawn in the literature is between 5-Amino-1MQ and direct NAD+ precursors such as NR and NMN. Both strategies aim to elevate intracellular NAD+ levels, but they differ in mechanism, tissue selectivity, and evidence base.

Direct precursors (NR, NMN) are substrates for biosynthetic enzymes and elevate NAD+ broadly across tissues that express the relevant transporters and kinases. Their safety profiles are relatively well characterized, with multiple human trials showing tolerability. 13 Their limitation is that they do not address the root cause of elevated NNMT-driven NAD+ depletion; in high-NNMT-expressing tissues, supplemented nicotinamide can simply be re-methylated and excreted, limiting the net effect.

5-Amino-1MQ, by contrast, targets the NNMT enzyme directly, potentially producing a more tissue-selective effect in compartments where NNMT is most active (liver, visceral adipose). It also simultaneously addresses the SAM cycle dysregulation associated with NNMT overexpression, which NAD+ precursors do not. The tradeoff is a much thinner evidence base, no human safety data, and higher per-milligram cost compared to NR or NMN.

Researchers choosing between these tools should consider: if the research question is primarily about NAD+ levels in a broad context, precursors are better characterized and more cost-effective. If the question is specifically about NNMT biology, adipose tissue metabolism, or the SAM-epigenome axis, 5-Amino-1MQ provides a mechanistic specificity that no nutrient supplement can match.

Comparative Analysis: NNMT Inhibition vs. Senolytic Approaches

The partial SASP-suppressive effect of 5-Amino-1MQ noted in preliminary data invites comparison with established senolytics such as quercetin and navitoclax. Classical senolytics work by inducing apoptosis in senescent cells via pro-apoptotic signaling, whereas NNMT inhibition appears to modulate the secretory phenotype of senescent cells without eliminating them. This is a senomorphic rather than senolytic mechanism, more analogous to rapamycin's effects on SASP than to quercetin's cytotoxic mechanism. 10

For researchers studying the intersection of metabolism and aging, combining an NNMT inhibitor with a classical senolytic could be a productive experimental design. However, combination studies of this kind have not been published, and any synergistic or antagonistic interactions between NNMT inhibition and apoptosis-pathway senolytics are unknown.

Where to Buy

Apollo Peptide Sciences is the affiliated vendor for this product. Their 5-Amino-1MQ 50mg vial is available at $80.00 and is supplied with a certificate of analysis documenting HPLC purity of at least 98% and mass-spec identity confirmation. Before purchasing, researchers should review the full product page and CoA documentation, available through the 5-Amino-1MQ product page.

For context on evaluating this and other vendors for research peptide and small-molecule procurement, see our suppliers overview, which covers quality indicators, shipping practices, payment security, and how to request and interpret vendor documentation.

When comparing vendors for this specific compound, the following minimum standards are advisable: HPLC purity at or above 98% by peak area, mass-spec identity confirmation with the expected molecular ion for the declared salt form, lot-specific CoA (not batch-generic), and responsive customer service capable of answering technical questions about analytical methods. Vendors unable to provide these represent unacceptable analytical risk for any published or grant-funded research project.

Pricing across the market for 5-Amino-1MQ ranges from approximately $60 to $120 per 50 mg vial depending on vendor, with per-milligram costs typically between $1.20 and $2.40. Price outliers on either end of this range warrant scrutiny: unusually low prices may indicate reduced purity or misrepresented identity, while very high prices are not consistently associated with superior analytical standards based on available CoA documentation in the research procurement community.

Open Research Questions

The research surrounding 5-Amino-1MQ and NNMT inhibition is genuinely promising, but several major questions remain unresolved and represent important directions for future investigation.

Optimal inhibition depth: Published studies have not systematically addressed what degree of NNMT inhibition (10%, 50%, 90% enzyme activity reduction) is necessary and sufficient to produce the observed metabolic benefits while minimizing risks from excessive SAM cycle disruption. Most published work has used doses that produce substantial but not necessarily complete inhibition, and the therapeutic window in terms of enzymatic activity has not been defined.

Tissue selectivity in vivo: Because NNMT is expressed at varying levels across tissues, systemic administration of 5-Amino-1MQ will produce heterogeneous pharmacodynamic effects by tissue. Whether hepatic and adipose NNMT inhibition can be achieved simultaneously with systemic dosing while sparing CNS and cardiac NNMT activity is not known. Targeted delivery approaches (nanoparticles, tissue-selective prodrug strategies) for NNMT inhibitors are an area of active interest but have not yet been validated with 5-Amino-1MQ specifically.

Long-term safety in genetic model systems: Chronic NNMT knockout mouse studies show a reasonably benign phenotype on standard diet, with improved metabolic responses on high-fat diet. 14 However, pharmacological inhibition differs from genetic knockout in timing, completeness, and reversibility of inhibition. Long-term (12+ month) pharmacological NNMT inhibition studies in rodents have not been published.

Cognitive and neurological effects: Limited data from neural and astrocytic cell models suggest NNMT may modulate inflammatory signaling in the CNS. Whether 5-Amino-1MQ crosses the blood-brain barrier in sufficient quantities to meaningfully inhibit brain NNMT, and whether this would be beneficial or harmful, remains an open question of particular relevance to cognitive longevity researchers. 2

Combination strategies: No published studies have examined 5-Amino-1MQ in combination with sirtuin activators, NAD+ precursors, senolytics, or mTOR inhibitors. Given the mechanistic interconnections between these pathways, combinatorial studies represent a scientifically well-motivated but currently unexplored research area.

Human pharmacology: The single most important knowledge gap is the complete absence of human pharmacokinetic, pharmacodynamic, or safety data. Until at least Phase I clinical data are published, the translational relevance of all animal model findings must remain cautiously hedged.

FAQ